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COMMENTARYTetralogy of Fallot repair: Ready for a new paradigmTal Geva, MDSince Alfred Blalock and Helen Taussig described the first
surgical treatment option for patients with tetralogy of Fal-
lot (TOF) in 1945, the management of this once nearly
uniformly lethal disease has evolved considerably. As a con-
sequence of seminal advances in management made during
the ensuing 6 decades, early surgical mortality has de-
creased from 50% in the late 1950s to less than 2% in
the modern surgical era.1,2 This remarkable success story,
however, is tempered by the realization that both past
and current surgical management strategies still result
in nearly universal residual hemodynamic and
electrophysiologic abnormalities. Consequently, patients
with repaired TOF face an increased mortality risk, which
manifests beginning in the third decade of life and
accelerates thereafter.3,4
Although some hemodynamic abnormalities associated
with TOF repair, such as residual ventricular septal defect,
are potentially avoidable, pulmonary regurgitation (PR)
resulting from reconstruction of the obstructed right
ventricular outflow tract (RVOT) is often impossible to
avoid without residual pulmonary stenosis (PS). Although
chronic PR was thought by most practitioners in the
1960s and 1970s to be a benign condition, its deleterious
hemodynamic consequences have gained considerable at-
tention during the past quarter century.5 It is now widely ac-
cepted that PR-induced right ventricular dilatation and
dysfunction, left ventricular dysfunction related to adverse
interactions with the volume overloaded and a dysfunc-
tional right ventricle (through abnormal septal geometry,
shared myofibers, and probably humoral factors), and elec-
tromechanical dyssynchrony all contribute to late morbid-
ity and excess mortality late after TOF repair.6 With that
realization in mind, surgeons have attempted to devise
strategies aimed at relieving RVOT obstruction while pre-
serving pulmonary valve competence. Striking an optimal
balance between residual PS and PR, however, has re-
mained elusive.7
In this issue of the Journal, Yoo and colleagues8 provide
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The Journal of Thoracic and Carpatients with repaired TOF. They report their institutional
experience with RVOT reconstruction in a series of 138 pa-
tients who were evaluated by echocardiography and cardiac
magnetic resonance imaging at a mean age of 17 years.
They retrospectively compared 51 patients who had both
PR and PS (defined as Doppler maximum instantaneous
gradient>25 mm Hg) with 87 patients who had PR but
no PS. The PR and PS group had less right ventricular dila-
tation and slightly higher right ventricular ejection fraction
than did the PR without PS group, despite their similar PR
fractions. They also noted modest correlations between
higher PS gradient and lower PR fraction and right ventric-
ular size, although the mechanism or mechanisms responsi-
ble for the observed differences in right ventricular size and
function remain unclear. Yoo and colleagues8 conclude that
RVOT reconstruction with ‘‘acceptable’’ residual PS is su-
perior to ‘‘aggressive’’ enlargement of the RVOT.
Although the results of this study support the current
trend among contemporary congenital cardiac surgeons to
preserve pulmonary valve function as much as possible dur-
ing TOF repair,9 it is important to understand that substan-
tial gaps in knowledge persist. The retrospective,
nonrandomized study design of Yoo and colleagues8 limits
our ability to discern the morphologic, hemodynamic, and
intraoperative variables that differed between the outcome
groups. Specifically, with similar rates of transannular patch
and only modest differences between groups in intraopera-
tive right ventricular pressure and right to left ventricular
pressure ratio, it is difficult to develop specific criteria for
intraoperative management. Furthermore, we do not know
whether the apparent advantage in laboratory values (lower
right ventricular diastolic and systolic volumes and slightly
higher right ventricular ejection fraction) actually translates
into superior clinical outcomes. The latter question is par-
ticularly important, because our knowledge of determinants
of clinical outcomes late after TOF repair is still evolving.
Although studies published during the last decade have
shown that severe right ventricular dilatation and dysfunc-
tion (as well as left ventricular dysfunction, regional right
ventricular wall motion abnormalities, history of syncope,
prolonged QRS duration (>180 ms), and sustained ventric-
ular tachycardia) are associated with heart failure and
death,10-14 more recent data paint a more complex picture.
Valente and coworkers,15 in a large, multicenter cohort
study, provided preliminary evidence that right ventricular
mass and mass-to-volume ratio are strongly associated
with sustained ventricular tachycardia and even death late
after TOF repair. In light of this information, and because
a higher degree of residual PS is likely to be associated
more severe right ventricular hypertrophy (which was notdiovascular Surgery c Volume 143, Number 6 1305
Commentary Gevameasured in the study of Yoo and colleagues8), we should
remain cautious about adopting a strategy that favors one
hemodynamic derangement (PS) over another (PR).
The ongoing quest for refinement of valve-sparing RVOT
reconstruction and the unresolved debate as to the optimal
balance between residual PS and PR highlight the urgent
need for a new paradigm in the surgical management of
TOF. Although small incremental improvements have an
important role, it is now necessary to develop a bioengi-
neered pulmonary valve substitute, as well as a contracting
RVOT patch with biomechanical properties that are as close
as possible to those of the myocardium. These biotechno-
logic leaps, which are currently being pursued by several
groups,16,17 will free us from having to choose the lesser
evil and bring us closer to a durable TOF repair rather
than palliation.
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